Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer

NCT06653972 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Her2-negative Metastatic Breast Cancer
Vinorelbine
Liposomal Doxorubicin

Interventions

DRUG: Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.

Sponsor

Wang Jiayu

Collaborators

[object Object]